Nurix Therapeutics Inc. Common stock (NRIX)
Stock · NASDAQ · Health Care
$24.39as of 10/16/2026
Price chart
Active signals
NRIX Signal Track Record
How signals performed across all stocks →What NRIX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | -2.5% | 46% | September 18, 2026 |
| Bollinger Band Breakout | 26 | +4.7% | 58% | August 4, 2026 |
| Bollinger Band Breakdown | 20 | -4.2% | 40% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 6 | -0.9% | 33% | June 5, 2026 |
| Any 20-session window (baseline) | -0.6% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 317
- Website
- www.nurixtx.com/
Fundamentals
- 1-day range
- $23.61$25.14
- Market cap
- $2.62B
- P/E (trailing)
- 9.25
- P/E (forward)
- -15.56
- EPS (trailing)
- $2.31
- Dividend yield
- —
- Beta
- 1.78
- Avg. volume
- 1.44M
How Nurix Therapeutics Inc. Common stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Jan 28, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
Nurix Therapeutics Inc. Common stock Competitors
Chosen by industry and closest market cap.
- NRIXNurix Therapeutics Inc. Common stock$24.42▼ 2.12%Market cap $2.62BP/E 9.25$9.14$28.23
- TRVITrevi Therapeutics Inc. Common Stock$11.88▼ 1.90%Market cap $2.63BP/E —$9.28$20.22
- PBHPrestige Consumer Healthcare Inc. Common Stock$49.92▲ 1.46%Market cap $2.58BP/E 13.50$42.62$71.07
- AMLXAmylyx Pharmaceuticals Inc. Common Stock$26.34▼ 4.74%Market cap $2.69BP/E —$10.83$41.14
- RAREUltragenyx Pharmaceutical Inc. Common Stock$14.54▼ 4.15%Market cap $2.54BP/E —$12.73$39.89
- SUPNSupernus Pharmaceuticals Inc. Common Stock$37.88▼ 4.27%Market cap $2.72BP/E —$39.36$59.68
- NKTRNektar Therapeutics Common Stock$35.78▼ 5.14%Market cap $2.48BP/E —$33.4$109
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NRIX Nurix Therapeutics Inc. Common stock | $2.62B | 9.25 | $24.42 | ▼ 2.12% | $9.14$28.23 |
| TRVI Trevi Therapeutics Inc. Common Stock | $2.63B | — | $11.88 | ▼ 1.90% | $9.28$20.22 |
| PBH Prestige Consumer Healthcare Inc. Common Stock | $2.58B | 13.50 | $49.92 | ▲ 1.46% | $42.62$71.07 |
| AMLX Amylyx Pharmaceuticals Inc. Common Stock | $2.69B | — | $26.34 | ▼ 4.74% | $10.83$41.14 |
| RARE Ultragenyx Pharmaceutical Inc. Common Stock | $2.54B | — | $14.54 | ▼ 4.15% | $12.73$39.89 |
| SUPN Supernus Pharmaceuticals Inc. Common Stock | $2.72B | — | $37.88 | ▼ 4.27% | $39.36$59.68 |
| NKTR Nektar Therapeutics Common Stock | $2.48B | — | $35.78 | ▼ 5.14% | $33.4$109 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $36benzinga · 10/16/2026
- Stock Market: Will S&P 500 Open Up or Down Today?Benzinga · 10/8/2026
- Is Extending the Gilead E3 Ligase Collaboration Altering The Investment Case For Nurix Therapeutics (NRIX)?Yahoo · 10/7/2026
- Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic LeukemiaYahoo · 10/7/2026
- Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche CollaborationBenzinga · 10/7/2026
- Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead SciencesYahoo · 10/5/2026
- Nurix Gets $10M As Gilead Extends Drug Discovery DealBenzinga · 10/5/2026
- Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with PfizerYahoo · 9/29/2026
- AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesYahoo · 9/21/2026
Insider Activity
Insider Actions →- Christine Ring · October 2, 2026 · Option Exercise5.8K @ $8.72
- Christine Ring · October 2, 2026 · Sale5.8K @ $23.19
- Christine Ring · September 2, 2026 · Option Exercise5.8K @ $8.72
- Christine Ring · September 2, 2026 · Sale400 @ $26.64
- Christine Ring · September 2, 2026 · Sale5.4K @ $25.69
- Gwenn Hansen · September 1, 2026 · Option Exercise1.5K @ $1.86
- Gwenn Hansen · September 1, 2026 · Sale1.5K @ $25.47
- Gwenn Hansen · August 5, 2026 · Option Exercise4.4K @ $1.86
- Gwenn Hansen · August 5, 2026 · Sale4.4K @ $25
- Gwenn Hansen · August 4, 2026 · Sale2.6K @ $24.64
- Gwenn Hansen · August 4, 2026 · Sale1.5K @ $23.87
- van Houte Hans · August 4, 2026 · Sale3.0K @ $24.65
- van Houte Hans · August 4, 2026 · Sale1.8K @ $23.89
- Christine Ring · August 3, 2026 · Option Exercise5.8K @ $8.72
- Christine Ring · August 3, 2026 · Sale16.6K @ $23.05
Institutional Ownership
March 31, 2026
- Total shares held
- 115.34M
- Total value held
- $1.72B
- Institutional holders
- 189
- Unknown8.93M
- Unknown7.73M
- Unknown6.50M
- Unknown6.35M
- Unknown5.54M
- Unknown5.14M
- Unknown4.93M
- Unknown4.66M
- Unknown4.43M
- Unknown4.10M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Nurix Advances Bexobrutideg Studies and Secures $10M Gilead Extension
Nurix has enrolled its first patient in a Phase 1b/2 study of Bexobrutideg for chronic lymphocytic leukemia, and a second enrollment began for a Bexobrutideg plus Venetoclax combination under a Roche partnership. The company also received a second research term extension for its oncology program with Gilead Sciences and secured $10 million from Gilead as part of the extended drug‑discovery collaboration. These developments show ongoing progress in Nurix’s pipeline and continued partnership support.
Nurix Advances Bexobrutideg Studies and Secures $10M Gilead Extension. Nurix has enrolled its first patient in a Phase 1b/2 study of Bexobrutideg for chronic lymphocytic leukemia, and a second enrollment began for a Bexobrutideg plus Venetoclax combination under a Roche partnership. The company also received a second research term extension for its oncology program with Gilead Sciences and secured $10 million from Gilead as part of the extended drug‑discovery collaboration. These developments show ongoing progress in Nurix’s pipeline and continued partnership support.